

---

**Product Data Sheet**

---

Product Name: (+)-Norfenfluramine

Cat. No.: GC68210

**Chemical Properties**

Cas. No. 19036-73-8

Formula  $C_{10}H_{12}F_3N$ 

M.Wt 203.2

Solubility DMSO : 100 mg/mL (492.13 mM; Need ultrasonic)

Storage 4°C, protect from light

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure **Background**

(+)-Norfenfluramine a major hepatic metabolite of (+)-fenfluramine, is a selective **5-HT<sub>2B</sub>** receptor agonist ( $K_i$ : 11.2 nM). (+)-Norfenfluramine potently stimulates the hydrolysis of inositol phosphates and increases intracellular  $Ca^{2+}$ . (+)-Norfenfluramine can be used for the research of primary pulmonary hypertension and valvular heart disease<sup>[1]</sup>.

(+)-Norfenfluramine (1 nM to 100  $\mu$ M) contracts arteries with a dramatic decrease in threshold (aorta and mesenteric resistance artery) in rats<sup>[1]</sup>.

(+)-Norfenfluramine (1 and 10  $\mu$ M, 3 min) induces contraction in aorta from tissues of normotensive and hypertensive rats<sup>[1]</sup>.

(+)-Norfenfluramine (0-10  $\mu$ M, 3 min) induces 5-HT release from rat hippocampal synaptosomes by  $Ca^{2+}$ -dependent way<sup>[2]</sup>.

(+)-Norfenfluramine (1-300  $\mu$ g/kg, i.v.) induces pressor response in conscious SHAM and DOCA-salt rats<sup>[1]</sup>.

(+)-Norfenfluramine (2.5 and 5 mg/kg, i.p.) decreases of 5-HT and 5-HIAA levels in

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

telencephalon and brainstem of rats<sup>[3]</sup>.

Animal Model: Conscious SHAM and DOCA-salt rats<sup>[1]</sup>.

Dosage: 1-300 µg/kg

Administration: Intravenous injection (i.v.), given in a cumulative fashion at 6-min intervals.

Result: Induced pressor response in conscious SHAM and DOCA-salt rats. (change in mean arterial blood pressure at 300 µg/kg, mm Hg, SHAM vehicle=36, SHAM ketanserin=7, DOCA=51, DOCA ketanserin=19).

[1]. Wei Ni, et al. The 5-hydroxytryptamine<sub>2A</sub> receptor is involved in (+)-norfenfluramine-induced arterial contraction and blood pressure increase in deoxycorticosterone acetate-salt hypertension. *J Pharmacol Exp Ther.* 2007 May;321(2):485-91.

[2]. M Gobbi, et al. In vitro studies on the mechanism by which (+)-norfenfluramine induces serotonin and dopamine release from the vesicular storage pool. *Naunyn Schmiedebergs Arch Pharmacol.* 1998 Sep;358(3):323-7.

[3]. R Invernizzi, et al. Is receptor activation involved in the mechanism by which (+)-fenfluramine and (+)-norfenfluramine deplete 5-hydroxytryptamine in the rat brain? *Br J Pharmacol.* 1982 Mar;75(3):525-30.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA